MARKET

CLNN

CLNN

CLENE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.08
-0.18
-2.48%
After Hours: 7.08 0 0.00% 16:00 09/24 EDT
OPEN
7.13
PREV CLOSE
7.26
HIGH
7.27
LOW
6.96
VOLUME
95.91K
TURNOVER
--
52 WEEK HIGH
17.82
52 WEEK LOW
6.23
MARKET CAP
435.36M
P/E (TTM)
-5.6681
1D
5D
1M
3M
1Y
5Y
BRIEF-Clene Initiates Second FDA Expanded Access Program With CNM-Au8 For People With Amyotrophic Lateral Sclerosis
reuters.com · 2d ago
Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis
SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegener...
GlobeNewswire · 2d ago
Clene Announces Launch of 2nd FDA Expanded Access Program for Amyotrophic Lateral Sclerosis Treatment
MT Newswires · 2d ago
Clene Highlights Presentation Of Phase 2 CNM-Au8 Target Engagement Data At Int'l. Parkinson, Movement Disorder Society Congress
CNM-Au8® , a catalytically active gold nanocrystal suspension, significantly improved brain energetic metabolism in Parkinson’s patients SALT LAKE CITY, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Clene Inc.
Benzinga · 09/17 11:05
Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021
Clene Inc. (NASDAQ: CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energet...
GlobeNewswire · 09/17 11:00
BRIEF-Clene Completes Final Patient Visit In Phase 2 Rescue-Als Study Topline Data Readout Expected Q4 2021
reuters.com · 09/09 12:12
Clene Completes Final Patient Visit In Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
Benzinga · 09/09 11:18
What Percentage Of Clene Inc. (NASDAQ:CLNN) Shares Do Insiders Own?
If you want to know who really controls Clene Inc. ( NASDAQ:CLNN ), then you'll have to look at the makeup of its share...
Simply Wall St. · 09/07 12:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLNN. Analyze the recent business situations of CLENE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLNN stock price target is 22.75 with a high estimate of 25.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 4.61M
% Owned: 7.49%
Shares Outstanding: 61.49M
TypeInstitutionsShares
Increased
10
1.88M
New
19
674.04K
Decreased
4
13.88K
Sold Out
8
421.55K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Shalom Jacobovitz
President/Chief Executive Officer/Director
Robert Etherington
Co-Founder/Chief Scientific Officer
Mark Mortenson
Chief Financial Officer
Ted Jeong
Other
Robert Glanzman
Director
Reed Wilcox
Independent Director
Fiona Costello
Independent Director
Jonathan Gay
Independent Director
David Matlin
Independent Director
Vallerie Mclaughlin
Independent Director
Alison Mosca
Independent Director
John Stevens
Independent Director
Chidozie Ugwumba
No Data
About CLNN
Clene Inc, formerly Tottenham Acquisition I Ltd, is a company mainly engaged in the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The Company develops an electrochemistry drug development platform that draws from nanotechnology, plasma physics, material science, and biochemistry. The Company’s products include CNM-Au8, CNM-ZnAg, CNM-AgZn-17 and CNM-AuPt7. Its CSN therapeutic candidates aim to address high unmet medical needs in several disease areas including disease modification of central nervous system disorders, the treatment of infectious diseases, accelerated wound healing and scar formation, and the treatment of several cancer types.

Webull offers kinds of Clene Inc. stock information, including NASDAQ:CLNN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLNN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLNN stock methods without spending real money on the virtual paper trading platform.